BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Front Immunol 2021;12:636568. [PMID: 33767702 DOI: 10.3389/fimmu.2021.636568] [Cited by in Crossref: 182] [Cited by in F6Publishing: 174] [Article Influence: 91.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Z, Wei X. Artificial intelligence-assisted selection and efficacy prediction of antineoplastic strategies for precision cancer therapy. Semin Cancer Biol 2023;90:57-72. [PMID: 36796530 DOI: 10.1016/j.semcancer.2023.02.005] [Reference Citation Analysis]
2 Regal JA, Guerra García ME, Jain V, Chandramohan V, Ashley DM, Gregory SG, Thompson EM, López GY, Reitman ZJ. Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population. Acta Neuropathol Commun 2023;11:50. [PMID: 36966348 DOI: 10.1186/s40478-023-01548-3] [Reference Citation Analysis]
3 Kloosterman DJ, Akkari L. Macrophages at the interface of the co-evolving cancer ecosystem. Cell 2023:S0092-8674(23)00163-0. [PMID: 36924769 DOI: 10.1016/j.cell.2023.02.020] [Reference Citation Analysis]
4 Steinfass T, Poelchen J, Sun Q, Mastrogiulio G, Novak D, Vierthaler M, Pardo S, Federico A, Hüser L, Hielscher T, Carretero R, Offringa R, Altevogt P, Umansky V, Utikal J. Secretogranin II influences the assembly and function of MHC class I in melanoma. Exp Hematol Oncol 2023;12:29. [PMID: 36906639 DOI: 10.1186/s40164-023-00387-1] [Reference Citation Analysis]
5 Yang C, Li D, Ko C, Wang K, Wang H. Active ingredients of traditional Chinese medicine for enhancing the effect of tumor immunotherapy. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1133050] [Reference Citation Analysis]
6 Liu Y, Wang Y, Yang Y, Weng L, Wu Q, Zhang J, Zhao P, Fang L, Shi Y, Wang P. Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct Target Ther 2023;8:104. [PMID: 36882399 DOI: 10.1038/s41392-023-01365-z] [Reference Citation Analysis]
7 Shin S, Lee P, Han J, Kim SN, Lim J, Park DH, Paik T, Min J, Park CG, Park W. Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy. Tissue Eng Regen Med 2023;:1-17. [PMID: 36867402 DOI: 10.1007/s13770-022-00515-8] [Reference Citation Analysis]
8 Nilsson AR, Xian H, Shalapour S, Cammenga J, Karin M. IRF1 regulates self-renewal and stress-responsiveness to support hematopoietic stem cell maintenance. bioRxiv 2023:2023. [PMID: 36747722 DOI: 10.1101/2023.01.24.525321] [Reference Citation Analysis]
9 Castillo J, Xue T, Joseph S, Norwood M, Mullen DJ, Berrellez S, James S, Epstein AL, Mceachron T, Marconett CN. LINC00261expression reduces mutation accumulation while conferring resistance to cisplatin and altering the tumor-immune microenvironment in lung adenocarcinoma.. [DOI: 10.1101/2023.03.02.530823] [Reference Citation Analysis]
10 Ding Y, Zheng D, Xie L, Zhang X, Zhang Z, Wang L, Hu ZW, Yang Z. Enzyme-Instructed Peptide Assembly Favored by Preorganization for Cancer Cell Membrane Engineering. J Am Chem Soc 2023;145:4366-71. [PMID: 36669158 DOI: 10.1021/jacs.2c11823] [Reference Citation Analysis]
11 McBrearty N, Cho C, Chen J, Zahedi F, Peck AR, Radaelli E, Assenmacher CA, Pavlak C, Devine A, Yu P, Lu Z, Zhang H, Li J, Pitarresi JR, Astsaturov I, Cukierman E, Rustgi AK, Stanger BZ, Rui H, Fuchs SY. Tumor-Suppressive and Immune-Stimulating Roles of Cholesterol 25-hydroxylase in Pancreatic Cancer Cells. Mol Cancer Res 2023;21:228-39. [PMID: 36378658 DOI: 10.1158/1541-7786.MCR-22-0602] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wang W, Qiu T, Li F, Ren S. Current status and future perspectives of bispecific antibodies in the treatment of lung cancer. Chin Med J (Engl) 2023. [PMID: 36848213 DOI: 10.1097/CM9.0000000000002460] [Reference Citation Analysis]
13 Kaur A, Surnilla A, Zaitouna AJ, Basrur V, Mumphrey MB, Grigorova I, Cieslik M, Carrington M, Nesvizhskii AI, Raghavan M. Mass spectrometric profiling of HLA-B44 peptidomes provides evidence for tapasin-mediated tryptophan editing. bioRxiv 2023:2023. [PMID: 36909546 DOI: 10.1101/2023.02.26.530125] [Reference Citation Analysis]
14 Tallima H, El Ridi R. Mechanisms of Arachidonic Acid In Vitro Tumoricidal Impact. Molecules 2023;28. [PMID: 36838715 DOI: 10.3390/molecules28041727] [Reference Citation Analysis]
15 Kasravi M, Ahmadi A, Babajani A, Mazloomnejad R, Hatamnejad MR, Shariatzadeh S, Bahrami S, Niknejad H. Immunogenicity of decellularized extracellular matrix scaffolds: a bottleneck in tissue engineering and regenerative medicine. Biomater Res 2023;27:10. [PMID: 36759929 DOI: 10.1186/s40824-023-00348-z] [Reference Citation Analysis]
16 Lan BH, Becker M, Freund C. The mode of action of tapasin on major histocompatibility class I (MHC-I) molecules. J Biol Chem 2023;299:102987. [PMID: 36758805 DOI: 10.1016/j.jbc.2023.102987] [Reference Citation Analysis]
17 Xiao X, Wang Z, Kong Y, Lu H. Deep learning-based morphological feature analysis and the prognostic association study in colon adenocarcinoma histopathological images. Front Oncol 2023;13:1081529. [PMID: 36845699 DOI: 10.3389/fonc.2023.1081529] [Reference Citation Analysis]
18 Seok J, Cho SD, Seo SJ, Park SH. Roles of Virtual Memory T Cells in Diseases. Immune Netw 2023;23:e11. [PMID: 36911806 DOI: 10.4110/in.2023.23.e11] [Reference Citation Analysis]
19 Xi X, Deng T, Qiu F, Zhu Y, Li Y, Li G, Guo Y, Du B. Leukemia Inhibitory Factor Impairs the Function of Peripheral γδT Cells in Patients with Colorectal Cancer. Immunol Invest 2023;52:210-23. [PMID: 36507826 DOI: 10.1080/08820139.2022.2155182] [Reference Citation Analysis]
20 Liu Y, Liu X, Huang J, Shi Y, Luo Z, Zhang J, Guo X, Jiang M, Li X, Yin H, Qin B, Guan G, Luo L, Zhou Y, You J. Nonlysosomal Route of mRNA Delivery and Combining with Epigenetic Regulation Optimized Antitumor Immunoprophylactic Efficacy. Adv Healthc Mater 2023;12:e2202460. [PMID: 36366890 DOI: 10.1002/adhm.202202460] [Reference Citation Analysis]
21 Erlmeier F, Klümper N, Landgraf L, Strissel PL, Strick R, Sikic D, Taubert H, Wach S, Geppert CI, Bahlinger V, Breyer J, Ritter M, Bolenz C, Roghmann F, Erben P, Schwamborn K, Wirtz RM, Horn T, Wullich B, Hölzel M, Hartmann A, Gschwend JE, Weichert W, Eckstein M. Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition. Eur Urol 2023;83:133-42. [PMID: 36372626 DOI: 10.1016/j.eururo.2022.10.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Ait-ahmed Y, Lafdil F. Novel insights into the impact of liver inflammatory responses on primary liver cancer development. Liver Research 2023. [DOI: 10.1016/j.livres.2023.01.001] [Reference Citation Analysis]
23 Mumphrey MB, Li GX, Hosseini N, Nesvizhskii A, Cieslik M. HLAProphet: Personalized allele-level quantification of the HLA proteins.. [DOI: 10.1101/2023.01.29.526142] [Reference Citation Analysis]
24 Zhang C, Peng L, Gu H, Wang J, Wang Y, Xu Z. ANXA10 is a prognostic biomarker and suppressor of hepatocellular carcinoma: a bioinformatics analysis and experimental validation. Sci Rep 2023;13:1583. [PMID: 36709331 DOI: 10.1038/s41598-023-28527-x] [Reference Citation Analysis]
25 Hiltner T, Szörenyi N, Kohlruss M, Hapfelmeier A, Herz AL, Slotta-Huspenina J, Jesinghaus M, Novotny A, Lange S, Ott K, Weichert W, Keller G. Significant Tumor Regression after Neoadjuvant Chemotherapy in Gastric Cancer, but Poor Survival of the Patient? Role of MHC Class I Alterations. Cancers (Basel) 2023;15. [PMID: 36765729 DOI: 10.3390/cancers15030771] [Reference Citation Analysis]
26 Papadaki GF, Ani O, Florio TJ, Young MC, Danon JN, Sun Y, Dersh D, Sgourakis NG. Decoupling peptide binding from T cell receptor recognition with engineered chimeric MHC-I molecules. Front Immunol 2023;14:1116906. [PMID: 36761745 DOI: 10.3389/fimmu.2023.1116906] [Reference Citation Analysis]
27 Dos Reis JS, Diniz-Lima I, Santos MARDC, Barcelos PM, da Costa KM, Valente RDC, Chaves LS, de Campos LP, Dos Santos AC, Correia de Lima RG, Decote-Ricardo D, Morrot A, Previato JO, Mendonça-Previato L, Freire-de-Lima CG, Fonseca LMD, Freire-de-Lima L. The Blessed Union of Glycobiology and Immunology: A Marriage That Worked. Medicines (Basel) 2023;10. [PMID: 36827215 DOI: 10.3390/medicines10020015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Gong X, Karchin R. Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy. Sci Rep 2023;13:950. [PMID: 36653470 DOI: 10.1038/s41598-023-28167-1] [Reference Citation Analysis]
29 Lin W, Chen L, Zhang H, Qiu X, Huang Q, Wan F, Le Z, Geng S, Zhang A, Qiu S, Chen L, Kong L, Lu JJ. Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation. Nat Commun 2023;14:265. [PMID: 36650153 DOI: 10.1038/s41467-022-35710-7] [Reference Citation Analysis]
30 Yoshida S, Kato TM, Sato Y, Umekage M, Ichisaka T, Tsukahara M, Takasu N, Yamanaka S. A clinical-grade HLA haplobank of human induced pluripotent stem cells matching approximately 40% of the Japanese population. Med (N Y) 2023;4:51-66.e10. [PMID: 36395757 DOI: 10.1016/j.medj.2022.10.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
31 Bignoux MJ, Otgaar TC, Bernert M, Weiss SFT, Ferreira E. Downregulation of LRP/LR with siRNA inhibits several cancer hallmarks in lung cancer cells. FEBS Open Bio 2023;13:323-40. [PMID: 36579897 DOI: 10.1002/2211-5463.13544] [Reference Citation Analysis]
32 Hargadon KM. Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer. Cell Mol Life Sci 2023;80:40. [PMID: 36629955 DOI: 10.1007/s00018-023-04689-9] [Reference Citation Analysis]
33 Israr M, Lam F, DeVoti J, Mace EM, Papayannakos C, Abramson A, Steinberg BM, Bonagura VR. PGE(2) expression by HPV6/11-induced respiratory papillomas blocks NK cell activation in patients with recurrent respiratory papillomatosis. Eur J Immunol 2023;:e2250036. [PMID: 36608264 DOI: 10.1002/eji.202250036] [Reference Citation Analysis]
34 DuPont M, Visca H, Moshnikova A, Engelman DM, Reshetnyak YK, Andreev OA. Tumor treatment by pHLIP-targeted antigen delivery. Front Bioeng Biotechnol 2022;10:1082290. [PMID: 36686229 DOI: 10.3389/fbioe.2022.1082290] [Reference Citation Analysis]
35 Attalla S, Taifour T, Muller W. Tailoring therapies to counter the divergent immune landscapes of breast cancer. Front Cell Dev Biol 2023;11:1111796. [PMID: 36910138 DOI: 10.3389/fcell.2023.1111796] [Reference Citation Analysis]
36 Garcia-Recio S, Hinoue T, Wheeler GL, Kelly BJ, Garrido-Castro AC, Pascual T, De Cubas AA, Xia Y, Felsheim BM, McClure MB, Rajkovic A, Karaesmen E, Smith MA, Fan C, Ericsson PIG, Sanders ME, Creighton CJ, Bowen J, Leraas K, Burns RT, Coppens S, Wheless A, Rezk S, Garrett AL, Parker JS, Foy KK, Shen H, Park BH, Krop I, Anders C, Gastier-Foster J, Rimawi MF, Nanda R, Lin NU, Isaacs C, Marcom PK, Storniolo AM, Couch FJ, Chandran U, Davis M, Silverstein J, Ropelewski A, Liu MC, Hilsenbeck SG, Norton L, Richardson AL, Symmans WF, Wolff AC, Davidson NE, Carey LA, Lee AV, Balko JM, Hoadley KA, Laird PW, Mardis ER, King TA, Perou CM; AURORA US Network. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nat Cancer 2023;4:128-47. [PMID: 36585450 DOI: 10.1038/s43018-022-00491-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Chong CY, Goh MS, Porceddu SV, Rischin D, Lim AM. The Current Treatment Landscape of Cutaneous Squamous Cell Carcinoma. Am J Clin Dermatol 2023;24:25-40. [PMID: 36512176 DOI: 10.1007/s40257-022-00742-8] [Reference Citation Analysis]
38 Lehmann J, Caduff N, Krzywińska E, Stierli S, Salas-Bastos A, Loos B, Levesque MP, Dummer R, Stockmann C, Münz C, Diener J, Sommer L. Escape from NK cell tumor surveillance by NGFR-induced lipid remodeling in melanoma. Sci Adv 2023;9:eadc8825. [PMID: 36638181 DOI: 10.1126/sciadv.adc8825] [Reference Citation Analysis]
39 Wang Q, Li Z, Zhou S, Li Z, Huang X, He Y, Zhang Y, Zhao X, Tang Y, Xu M. NCAPG2 could be an immunological and prognostic biomarker: From pan-cancer analysis to pancreatic cancer validation. Front Immunol 2023;14:1097403. [PMID: 36776838 DOI: 10.3389/fimmu.2023.1097403] [Reference Citation Analysis]
40 Waad Sadiq Z, Brioli A, Al-Abdulla R, Çetin G, Schütt J, Murua Escobar H, Krüger E, Ebstein F. Immunogenic cell death triggered by impaired deubiquitination in multiple myeloma relies on dysregulated type I interferon signaling. Front Immunol 2023;14:982720. [PMID: 36936919 DOI: 10.3389/fimmu.2023.982720] [Reference Citation Analysis]
41 Li X, Guo X, Huang J, Lin Q, Qin B, Jiang M, Shan X, Luo Z, Zhang J, Shi Y, Lu Y, Liu X, Du Y, Yang F, Luo L, You J. Recruiting T cells and sensitizing tumors to NKG2D immune surveillance for robust antitumor immune response. J Control Release 2023;353:943-55. [PMID: 36535542 DOI: 10.1016/j.jconrel.2022.12.032] [Reference Citation Analysis]
42 Sorteberg AL, Ek L, Lilienthal I, Herold N. Immunotherapy of Osteosarcoma. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_236-1] [Reference Citation Analysis]
43 Yasunaga M. Development of Next-Generation Antibody Therapeutics Using DDS and Molecular Imaging. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_200-1] [Reference Citation Analysis]
44 Zhang Y, Li L, Chu F, Zhang L, Zhang L, Wu H, Li K. The tumor microenvironment in gastrointestinal adenocarcinomas revealed a prognostic and immunotherapeutic biomarker. Aging (Albany NY) 2022;14:10171-216. [PMID: 36585927 DOI: 10.18632/aging.204463] [Reference Citation Analysis]
45 Ebelt ND, Manuel ER. 5-Azacytidine-Mediated Modulation of the Immune Microenvironment in Murine Acute Myeloid Leukemia. Cancers (Basel) 2022;15. [PMID: 36612115 DOI: 10.3390/cancers15010118] [Reference Citation Analysis]
46 Najaflou M, Shahgolzari M, Khosroushahi AY, Fiering S. Tumor-Derived Extracellular Vesicles in Cancer Immunoediting and Their Potential as Oncoimmunotherapeutics. Cancers (Basel) 2022;15. [PMID: 36612080 DOI: 10.3390/cancers15010082] [Reference Citation Analysis]
47 Yang B, Li X, Zhang W, Fan J, Zhou Y, Li W, Yin J, Yang X, Guo E, Li X, Fu Y, Liu S, Hu D, Qin X, Dou Y, Xiao R, Lu F, Wang Z, Qin T, Wang W, Zhang Q, Li S, Ma D, Mills GB, Chen G, Sun C. Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis. Cell Rep Med 2022;3:100856. [PMID: 36543113 DOI: 10.1016/j.xcrm.2022.100856] [Reference Citation Analysis]
48 Mehranzadeh E, Crende O, Badiola I, Garcia-Gallastegi P. What Are the Roles of Proprotein Convertases in the Immune Escape of Tumors? Biomedicines 2022;10. [PMID: 36552048 DOI: 10.3390/biomedicines10123292] [Reference Citation Analysis]
49 Kumar V, Bauer C, Stewart JH. Chasing Uterine Cancer with NK Cell-Based Immunotherapies. Future Pharmacology 2022;2:642-659. [DOI: 10.3390/futurepharmacol2040039] [Reference Citation Analysis]
50 Kirtane K, St John M, Fuentes-Bayne H, Patel SP, Mardiros A, Xu H, Ng EW, Go WY, Wong DJ, Sunwoo JB, Welch JS. Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas. J Clin Med 2022;11. [PMID: 36555876 DOI: 10.3390/jcm11247259] [Reference Citation Analysis]
51 Lewicky JD, Martel AL, Fraleigh NL, Picard E, Mousavifar L, Nakamura A, Diaz-Mitoma F, Roy R, Le HT. Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer Immunotherapy. Pharmaceutics 2022;14. [PMID: 36559204 DOI: 10.3390/pharmaceutics14122710] [Reference Citation Analysis]
52 Yu Z, Vyungura O, Zhao Y. Molecular subtyping and IMScore based on immune-related pathways, oncogenic pathways, and DNA damage repair pathways for guiding immunotherapy in hepatocellular carcinoma patients. J Gastrointest Oncol 2022;13:3135-53. [PMID: 36636061 DOI: 10.21037/jgo-22-1101] [Reference Citation Analysis]
53 Shahbandi A, Chiu FY, Ungerleider NA, Kvadas R, Mheidly Z, Sun MJS, Tian D, Waizman DA, Anderson AY, Machado HL, Pursell ZF, Rao SG, Jackson JG. Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80. Nat Cancer 2022;3:1513-33. [PMID: 36482233 DOI: 10.1038/s43018-022-00466-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Nasr D, Kumar PA, Zerdan MB, Ghelani G, Dutta D, Graziano S, Lim SH. Radioimmunoconjugates in the age of modern immuno-oncology. Life Sciences 2022;310:121126. [DOI: 10.1016/j.lfs.2022.121126] [Reference Citation Analysis]
55 Salehi S, Ghaderi H, Habibi-Anbouhi M, Shoari A, Hassanzadeh Eskafi A, Sabouri A, Hosseininejad-Chafi M, Ashja Ardalan A, Ramezani B, Kazemi-Lomedasht F, Behdani M. Tumor Suppression by PD-1/PD-L1 Interaction Blockage in Mice Model. Iran J Pharm Res 2022;21:e132329. [PMID: 36896323 DOI: 10.5812/ijpr-132329] [Reference Citation Analysis]
56 Geng N, Hu T, He C. Identification of DDX60 as a Regulator of MHC-I Class Molecules in Colorectal Cancer. Biomedicines 2022;10. [PMID: 36551849 DOI: 10.3390/biomedicines10123092] [Reference Citation Analysis]
57 Xu Y, Xiong J, Sun X, Gao H. Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy. Acta Pharm Sin B 2022;12:4327-47. [PMID: 36561994 DOI: 10.1016/j.apsb.2022.11.001] [Reference Citation Analysis]
58 Matsushima S, Ajiro M, Iida K, Chamoto K, Honjo T, Hagiwara M. Chemical induction of splice-neoantigens attenuates tumor growth in a preclinical model of colorectal cancer. Sci Transl Med 2022;14:eabn6056. [PMID: 36449604 DOI: 10.1126/scitranslmed.abn6056] [Reference Citation Analysis]
59 Chang L, Zhu W, Jiang J. Albinism in the largest extant amphibian: A metabolic, endocrine, or immune problem? Front Endocrinol (Lausanne) 2022;13:1053732. [PMID: 36518250 DOI: 10.3389/fendo.2022.1053732] [Reference Citation Analysis]
60 Shevyrev DV, Tereshchenko VP, Sennikov SV. The Enigmatic Nature of the TCR-pMHC Interaction: Implications for CAR-T and TCR-T Engineering. Int J Mol Sci 2022;23. [PMID: 36499057 DOI: 10.3390/ijms232314728] [Reference Citation Analysis]
61 Noman MZ, Bocci IA, Karam M, Moer KV, Bosseler M, Kumar A, Berchem G, Auclair C, Janji B. The β-carboline Harmine improves the therapeutic benefit of anti-PD1 in melanoma by increasing the MHC-I-dependent antigen presentation. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.980704] [Reference Citation Analysis]
62 Wei M, Zuo S, Chen Z, Qian P, Zhang Y, Kong L, Gao H, Wei J, Dong J. Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1017574] [Reference Citation Analysis]
63 Alexandraki A, Strati K. Decitabine Treatment Induces a Viral Mimicry Response in Cervical Cancer Cells and Further Sensitizes Cells to Chemotherapy. Int J Mol Sci 2022;23. [PMID: 36430521 DOI: 10.3390/ijms232214042] [Reference Citation Analysis]
64 Gomez S, Cox OL, Walker RR 3rd, Rentia U, Hadley M, Arthofer E, Diab N, Grundy EE, Kanholm T, McDonald JI, Kobyra J, Palmer E, Noonepalle S, Villagra A, Leitenberg D, Bollard CM, Saunthararajah Y, Chiappinelli KB. Inhibiting DNA methylation and RNA editing upregulates immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer. J Immunother Cancer 2022;10. [PMID: 36343976 DOI: 10.1136/jitc-2022-004974] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
65 Yu L, Zhang MM, Hou JG. Molecular and cellular pathways in colorectal cancer: apoptosis, autophagy and inflammation as key players. Scand J Gastroenterol 2022;57:1279-90. [PMID: 35732586 DOI: 10.1080/00365521.2022.2088247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Ma X, Chan TA. Solving the puzzle of what makes immunotherapies work. Trends Cancer 2022;8:890-900. [PMID: 35933298 DOI: 10.1016/j.trecan.2022.06.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
67 Harkus U, Wankell M, Palamuthusingam P, McFarlane C, Hebbard L. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data. Semin Cancer Biol 2022;86:799-815. [PMID: 35065242 DOI: 10.1016/j.semcancer.2022.01.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
68 Hudson K, Cross N, Jordan-mahy N, Leyland R. Programmed death-ligand 1 expression in human cancer three-dimensional cell culture models.. [DOI: 10.1101/2022.10.31.514495] [Reference Citation Analysis]
69 Deng G, Zhou L, Wang B, Sun X, Zhang Q, Chen H, Wan N, Ye H, Wu X, Sun D, Sun Y, Cheng H. Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation. J Immunother Cancer 2022;10:e004874. [PMID: 36307151 DOI: 10.1136/jitc-2022-004874] [Reference Citation Analysis]
70 Wei Q, Taskén K. Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development. Biochemical Journal 2022;479:2219-2260. [DOI: 10.1042/bcj20210233] [Reference Citation Analysis]
71 Lu S, Barry MA. Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses. Expert Opinion on Biological Therapy 2022. [DOI: 10.1080/14712598.2022.2139601] [Reference Citation Analysis]
72 Jungles KM, Holcomb EA, Pearson AN, Jungles KR, Bishop CR, Pierce LJ, Green MD, Speers CW. Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1022542] [Reference Citation Analysis]
73 Moshnikova A, Dupont M, Visca H, Engelman DM, Andreev OA, Reshetnyak YK. Eradication of tumors and development of anti-cancer immunity using STINGa targeted by pHLIP. Front Oncol 2022;12:1023959. [DOI: 10.3389/fonc.2022.1023959] [Reference Citation Analysis]
74 Hoover AR, Kaabinejadian S, Krawic JR, Sun XH, Naqash AR, Yin Q, Yang X, Christopher Garcia K, Davis MM, Hildebrand WH, Chen WR. Localized ablative immunotherapy drives de novo CD8(+) T-cell responses to poorly immunogenic tumors. J Immunother Cancer 2022;10. [PMID: 36253002 DOI: 10.1136/jitc-2022-004973] [Reference Citation Analysis]
75 Wang K, Wang M, Li Z, Hu B, Wu J, Yuan Z, Wu X, Yuan Q, Yuan F. An antigen processing and presentation signature for prognostic evaluation and immunotherapy selection in advanced gastric cancer. Front Immunol 2022;13:992060. [DOI: 10.3389/fimmu.2022.992060] [Reference Citation Analysis]
76 Pabst L, Lopes S, Kotovskaya M, Bertrand B, Mascaux C. Biomarqueurs en immunothérapie, signatures moléculaires, radiomique : avons-nous avancé ? Revue des Maladies Respiratoires Actualités 2022;14:2S225-2S232. [DOI: 10.1016/s1877-1203(22)00122-7] [Reference Citation Analysis]
77 Li R, Chen Z, Li J, Dai Z, Yu Y. Nano-drug delivery systems for T cell-based immunotherapy. Nano Today 2022;46:101621. [DOI: 10.1016/j.nantod.2022.101621] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
78 Meskyte E, Pezzè L, Forcato M, Bocci I, Bisio A, Bicciato S, Baltriukienė D, Ciribilli Y. ETV7 reduces inflammatory responses in breast cancer cells by repressing the TNFR1/NF-κB axis.. [DOI: 10.21203/rs.3.rs-2067615/v1] [Reference Citation Analysis]
79 Johansson T, Partanen J, Saavalainen P. HLA allele-specific expression: Methods, disease associations, and relevance in hematopoietic stem cell transplantation. Front Immunol 2022;13:1007425. [DOI: 10.3389/fimmu.2022.1007425] [Reference Citation Analysis]
80 Cherry ABC, Gherardin NA, Sikder HI. Intracellular radar: Understanding γδ T cell immune surveillance and implications for clinical strategies in oncology. Front Oncol 2022;12:1011081. [DOI: 10.3389/fonc.2022.1011081] [Reference Citation Analysis]
81 Chen J, Hsieh Y, Chou C, Wu Y, Yang M, Chu S, Chao Y, Chen C. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice. IJMS 2022;23:10677. [DOI: 10.3390/ijms231810677] [Reference Citation Analysis]
82 Bhattacharjee R, Kumar L, Dhasmana A, Mitra T, Dey A, Malik S, Kim B, Gundamaraju R. Governing HPV-related carcinoma using vaccines: Bottlenecks and breakthroughs. Front Oncol 2022;12:977933. [DOI: 10.3389/fonc.2022.977933] [Reference Citation Analysis]
83 Chauhan P, Hu S, Sheng WS, Lokensgard JR. Regulatory T-Cells Suppress Cytotoxic T Lymphocyte Responses against Microglia. Cells 2022;11:2826. [PMID: 36139401 DOI: 10.3390/cells11182826] [Reference Citation Analysis]
84 Sun Y, Han R, Wang J, Qin Y, Ren Z, Feng X, Liu Q, Wang X. A single-beam of light priming the immune responses and boosting cancer photoimmunotherapy. J Control Release 2022;350:734-47. [PMID: 36063959 DOI: 10.1016/j.jconrel.2022.08.057] [Reference Citation Analysis]
85 Meškytė EM, Pezzè L, Forcato M, Bocci IA, Bisio A, Bicciato S, Baltriukienė D, Ciribilli Y. ETV7 reduces inflammatory responses in breast cancer cells by repressing TNFR1/NF-κB axis.. [DOI: 10.1101/2022.09.06.506542] [Reference Citation Analysis]
86 Fu X, Yang Y, Zhang X. A necroptosis -related signature for predicting prognosis and immunotherapy in hepatocellular carcinoma. Front Genet 2022;13:919599. [DOI: 10.3389/fgene.2022.919599] [Reference Citation Analysis]
87 Dutta A, Paul S. Exosome‐based cancer stem cell communication: Implication for detecting and eliminating cancer stem cells. MedComm – Future Medicine 2022;1. [DOI: 10.1002/mef2.23] [Reference Citation Analysis]
88 Yu J, Wu X, Song J, Zhao Y, Li H, Luo M, Liu X. Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma. Front Pharmacol 2022;13:928226. [DOI: 10.3389/fphar.2022.928226] [Reference Citation Analysis]
89 Griffith BD, Turcotte S, Lazarus J, Lima F, Bell S, Delrosario L, Mcgue J, Krishnan S, Oneka MD, Nathan H, Smith JJ, D’angelica MI, Shia J, Di Magliano MP, Rao A, Frankel TL. MHC Class II Expression Influences the Composition and Distribution of Immune Cells in the Metastatic Colorectal Cancer Microenvironment. Cancers 2022;14:4092. [DOI: 10.3390/cancers14174092] [Reference Citation Analysis]
90 Dima D, Jiang D, Singh DJ, Hasipek M, Shah HS, Ullah F, Khouri J, Maciejewski JP, Jha BK. Multiple Myeloma Therapy: Emerging Trends and Challenges. Cancers 2022;14:4082. [DOI: 10.3390/cancers14174082] [Reference Citation Analysis]
91 Fan Y, He C. STAT1 Regulates the Expression of MHC-I Class Molecules in Ovarian Cancer. 2022 7th International Conference on Biomedical Signal and Image Processing (ICBIP) 2022. [DOI: 10.1145/3563737.3563746] [Reference Citation Analysis]
92 Wu K, Liu Z, Liang J, Zhang F, Zhang F, Wang Y, Lia T, Liu S, Zhu Y, Li X. Expression of glucocorticoid receptor (GR) and clinical significance in adrenocortical carcinoma. Front Endocrinol 2022;13:903824. [DOI: 10.3389/fendo.2022.903824] [Reference Citation Analysis]
93 Valeri A, García-ortiz A, Castellano E, Córdoba L, Maroto-martín E, Encinas J, Leivas A, Río P, Martínez-lópez J. Overcoming tumor resistance mechanisms in CAR-NK cell therapy. Front Immunol 2022;13:953849. [DOI: 10.3389/fimmu.2022.953849] [Reference Citation Analysis]
94 Woodward A, Faria GN, Harrison RG. Annexin A5 as a targeting agent for cancer treatment. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215857] [Reference Citation Analysis]
95 Sun K, Fan C, Zhang J, Ni H, Wang M, Zhang J, Li Q, Kuang B, Wang Z, Hou S, Gong N. Prevention of alloimmune rejection using XBP1-deleted bone marrow-derived dendritic cells in heart transplantation. The Journal of Heart and Lung Transplantation 2022. [DOI: 10.1016/j.healun.2022.08.010] [Reference Citation Analysis]
96 Maskalenko NA, Zhigarev D, Campbell KS. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nat Rev Drug Discov 2022;21:559-77. [PMID: 35314852 DOI: 10.1038/s41573-022-00413-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 21.0] [Reference Citation Analysis]
97 Gu Y, Rampotas A, Sweeney C, Roberts DJ, Chakraverty R. CAR‐T Cells and Recent Advances in Clinical Cellular Immunotherapy. Practical Transfusion Medicine 2022. [DOI: 10.1002/9781119665885.ch45] [Reference Citation Analysis]
98 A. Rakityanskaya I, S. Ryabova T, A. Kalashnikova A, S. Balasaniants G, D. Kaprin A, I. Ershov F, V. Kir’janova V, B. Korzhenevskaja T, V. Barbinov D, V. Ignatovskij A, Y. Grivtsova L, G. Isaeva V, A. Falaleeva N, I. Gil’ A, A. Berns S, V. Vasil’eva N, V. Dolgo-saburova J, V. Shagdileeva E, V. Frolova E, S. Astanina N. Perspective Chapter: The Role of Interferon Gamma in Clinical Medicine. Interferon - Immune Metabolism [Working Title] 2022. [DOI: 10.5772/intechopen.105476] [Reference Citation Analysis]
99 Lopez J, Anna F, Authié P, Pawlik A, Ku MW, Blanc C, Souque P, Moncoq F, Noirat A, Hardy D, Sougakoff W, Brosch R, Guinet F, Charneau P, Majlessi L. A lentiviral vector encoding fusion of light invariant chain and mycobacterial antigens induces protective CD4+ T cell immunity. Cell Rep 2022;40:111142. [PMID: 35905717 DOI: 10.1016/j.celrep.2022.111142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Aghamajidi A, Maleki Vareki S. The Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer. Cancers 2022;14:3563. [DOI: 10.3390/cancers14153563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
101 Müller L, Kschischo M, Vokuhl C, Stahl D, Gütgemann I. Stemness Correlates Inversely with MHC Class I Expression in Pediatric Small Round Blue Cell Tumors. Cancers (Basel) 2022;14. [PMID: 35892842 DOI: 10.3390/cancers14153584] [Reference Citation Analysis]
102 Zhang D, Li Q, Chen X, Nie X, Xue F, Xu W, Luan Y. An Injectable Hydrogel to Modulate T Cells for Cancer Immunotherapy. Small 2022;:e2202663. [PMID: 35843879 DOI: 10.1002/smll.202202663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Chye A, Allen I, Barnet M, Burnett DL. Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy. Front Oncol 2022;12:894015. [DOI: 10.3389/fonc.2022.894015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Prasad S, Saha P, Chatterjee B, Chaudhary AA, Lall R, Srivastava AK. Complexity of Tumor Microenvironment: Therapeutic Role of Curcumin and Its Metabolites. Nutr Cancer 2023;75:1-13. [PMID: 35818029 DOI: 10.1080/01635581.2022.2096909] [Reference Citation Analysis]
105 Li Z, Ma Z, Xue H, Shen R, Qin K, Zhang Y, Zheng X, Zhang G. Chromatin Separation Regulators Predict the Prognosis and Immune Microenvironment Estimation in Lung Adenocarcinoma. Front Genet 2022;13:917150. [DOI: 10.3389/fgene.2022.917150] [Reference Citation Analysis]
106 Zhao W, Jin L, Chen P, Li D, Gao W, Dong G. Colorectal cancer immunotherapy-Recent progress and future directions. Cancer Lett 2022;545:215816. [PMID: 35810989 DOI: 10.1016/j.canlet.2022.215816] [Reference Citation Analysis]
107 Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, Govaerts J, Naulaerts S, Berneman ZN, Beuselinck B, Bol KF, Borst J, Coosemans A, Datsi A, Fučíková J, Kinget L, Neyns B, Schreibelt G, Smits E, Sorg RV, Spisek R, Thielemans K, Tuyaerts S, De Vleeschouwer S, de Vries IJM, Xiao Y, Garg AD. Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. OncoImmunology 2022;11:2096363. [DOI: 10.1080/2162402x.2022.2096363] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
108 Aviles-Padilla K, Angelo LS, Fan D, Paust S. CXCR6(+) and NKG2C(+) Natural Killer Cells Are Distinct With Unique Phenotypic and Functional Attributes Following Bone Marrow Transplantation. Front Immunol 2022;13:886835. [PMID: 35844621 DOI: 10.3389/fimmu.2022.886835] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Minnar CM, Chariou PL, Horn LA, Hicks KC, Palena C, Schlom J, Gameiro SR. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies. J Immunother Cancer 2022;10:e004561. [PMID: 35764364 DOI: 10.1136/jitc-2022-004561] [Reference Citation Analysis]
110 Bakr MN, Takahashi H, Kikuchi Y. Analysis of Melanoma Gene Expression Signatures at the Single-Cell Level Uncovers 45-Gene Signature Related to Prognosis. Biomedicines 2022;10:1478. [DOI: 10.3390/biomedicines10071478] [Reference Citation Analysis]
111 Zhang Z, Kong X, Ligtenberg MA, van Hal-van Veen SE, Visser NL, de Bruijn B, Stecker K, van der Helm PW, Kuilman T, Hoefsmit EP, Vredevoogd DW, Apriamashvili G, Baars B, Voest EE, Klarenbeek S, Altelaar M, Peeper DS. RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells. Cell Rep Med 2022;3:100655. [PMID: 35688159 DOI: 10.1016/j.xcrm.2022.100655] [Reference Citation Analysis]
112 Koustas E, Trifylli EM, Sarantis P, Papadopoulos N, Karapedi E, Aloizos G, Damaskos C, Garmpis N, Garmpi A, Papavassiliou KA, Karamouzis MV, Papavassiliou AG. Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives. Int J Mol Sci 2022;23:6664. [PMID: 35743107 DOI: 10.3390/ijms23126664] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
113 Zhang Z, Bu L, Luo J, Guo J. Targeting protein kinases benefits cancer immunotherapy. Biochim Biophys Acta Rev Cancer 2022;:188738. [PMID: 35660645 DOI: 10.1016/j.bbcan.2022.188738] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
114 Mishra AK, Singh SK, Dayanandan S, Banerjee S, Chakraborty S, Gopal AB, Samal S, Poirah I, Chakraborty D, Bhattacharyya A. Hypoxia-driven metabolic heterogeneity and immune evasive behaviour of gastrointestinal cancers: Elements of a recipe for disaster. Cytokine 2022;156:155917. [PMID: 35660715 DOI: 10.1016/j.cyto.2022.155917] [Reference Citation Analysis]
115 Liu W, Sun P, Xia L, He X, Xia Z, Huang Y, Liu W, Li L, Chen L. A brain-enriched lncRNA shields cancer cells from immune-mediated killing for metastatic colonization in the brain. Proc Natl Acad Sci U S A 2022;119:e2200230119. [PMID: 35617432 DOI: 10.1073/pnas.2200230119] [Reference Citation Analysis]
116 Samarkina A, Youssef MK, Ostano P, Ghosh S, Ma M, Tassone B, Proust T, Chiorino G, Levesque MP, Dotto GP. Androgen Receptor is a Determinant of Melanoma targeted drug resistance.. [DOI: 10.1101/2022.05.27.493720] [Reference Citation Analysis]
117 Gong X, Li N, Sun C, Li Z, Xie H. A Four-Gene Prognostic Signature Based on the TEAD4 Differential Expression Predicts Overall Survival and Immune Microenvironment Estimation in Lung Adenocarcinoma. Front Pharmacol 2022;13:874780. [PMID: 35600867 DOI: 10.3389/fphar.2022.874780] [Reference Citation Analysis]
118 Kim SK, Cho SW. The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. Front Pharmacol 2022;13:868695. [DOI: 10.3389/fphar.2022.868695] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
119 Yudistira G, Dewi YA, Sudiro M. Platelet to Lymphocytes Ratio to Predict Nasopharyngeal Carcinoma Progressivity. Open Access Maced J Med Sci 2022;10:2189-2194. [DOI: 10.3889/oamjms.2022.9659] [Reference Citation Analysis]
120 Zhang Z, Liu F, Chen W, Liao Z, Zhang W, Zhang B, Liang H, Chu L, Zhang Z. The importance of N6-methyladenosine modification in tumor immunity and immunotherapy. Exp Hematol Oncol 2022;11:30. [PMID: 35590394 DOI: 10.1186/s40164-022-00281-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
121 Hu X, Chen Z, Wang Z, Xiao Q. Cancer evolution: special focus on the immune aspect of cancer. Semin Cancer Biol 2022:S1044-579X(22)00117-1. [PMID: 35589072 DOI: 10.1016/j.semcancer.2022.05.006] [Reference Citation Analysis]
122 Slotta-huspenina J, Schwamborn K, Steiger K, Simon R, Kirchhoff FP, Büchler JW, Fiedler J, Retz M, Nawroth R, Ritschel C, Gschwend JE, Horn T. MHC I Expression Predicts Response to Checkpoint Inhibitors in Metastatic Urothelial Carcinoma but Lacks Prognostic Value in Localized Disease. BLC 2022;1:1-8. [DOI: 10.3233/blc-211604] [Reference Citation Analysis]
123 Li J, Smalley I, Chen Z, Wu JY, Phadke MS, Teer JK, Nguyen T, Karreth FA, Koomen JM, Sarnaik AA, Zager JS, Khushalani NI, Tarhini AA, Sondak VK, Rodriguez PC, Messina JL, Chen YA, Smalley KSM. Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. Clin Cancer Res 2022;28:2131-46. [PMID: 35247927 DOI: 10.1158/1078-0432.CCR-21-3145] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 12.0] [Reference Citation Analysis]
124 Krstic J, Deutsch A, Fuchs J, Gauster M, Gorsek Sparovec T, Hiden U, Krappinger JC, Moser G, Pansy K, Szmyra M, Gold D, Feichtinger J, Huppertz B. (Dis)similarities between the Decidual and Tumor Microenvironment. Biomedicines 2022;10:1065. [DOI: 10.3390/biomedicines10051065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
125 Shafer P, Kelly LM, Hoyos V. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects. Front Immunol 2022;13:835762. [PMID: 35309357 DOI: 10.3389/fimmu.2022.835762] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
126 Eisemann T, Wechsler-Reya RJ. Coming in from the cold: overcoming the hostile immune microenvironment of medulloblastoma. Genes Dev 2022;36:514-32. [PMID: 35680424 DOI: 10.1101/gad.349538.122] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
127 Aiken TJ, Erbe AK, Zebertavage L, Komjathy D, Feils AS, Rodriguez M, Stuckwisch A, Gillies SD, Morris ZS, Birstler J, Rakhmilevich AL, Sondel PM. Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma. J Immunother Cancer 2022;10. [PMID: 35618290 DOI: 10.1136/jitc-2022-004834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
128 Gorris MAJ, van der Woude LL, Kroeze LI, Bol K, Verrijp K, Amir AL, Meek J, Textor J, Figdor CG, de Vries IJM. Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome. J Immunother Cancer 2022;10:e004329. [PMID: 35550553 DOI: 10.1136/jitc-2021-004329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Bucova M, Kluckova K, Kozak J, Rychly B, Suchankova M, Svajdler M, Matejcik V, Steno J, Zsemlye E, Durmanova V. HLA-G 14bp Ins/Del Polymorphism, Plasma Level of Soluble HLA-G, and Association with IL-6/IL-10 Ratio and Survival of Glioma Patients. Diagnostics (Basel) 2022;12:1099. [PMID: 35626255 DOI: 10.3390/diagnostics12051099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Jung K, Son MJ, Lee SY, Kim JA, Ko DH, Yoo S, Kim CH, Kim YS. Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8+ T cells for cancer immunotherapy. Mol Cancer 2022;21:102. [PMID: 35459256 DOI: 10.1186/s12943-022-01574-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
131 Seaver K, Kourko O, Gee K, Greer PA, Basta S. IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model. Front Immunol 2022;13:884827. [DOI: 10.3389/fimmu.2022.884827] [Reference Citation Analysis]
132 Sebastian M, Divita Dean B, T. Flores C. Immunotherapy against Gliomas. Brain Tumors 2022. [DOI: 10.5772/intechopen.101386] [Reference Citation Analysis]
133 Lautert-dutra W, Melo CM, Chaves LP, dos Reis RB, Squire JA. Quantitative MHC class-I/-II expression levels in CDK12 mutated prostate cancer patients reveal intratumorally T cell adaptive immune response in tumors.. [DOI: 10.1101/2022.04.16.487364] [Reference Citation Analysis]
134 Tuomela K, Ambrose AR, Davis DM. Escaping Death: How Cancer Cells and Infected Cells Resist Cell-Mediated Cytotoxicity. Front Immunol 2022;13:867098. [PMID: 35401556 DOI: 10.3389/fimmu.2022.867098] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
135 Pishesha N, Harmand TJ, Ploegh HL. A guide to antigen processing and presentation. Nat Rev Immunol 2022. [PMID: 35418563 DOI: 10.1038/s41577-022-00707-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
136 Hussain A. Therapeutic applications of engineered chimeric antigen receptors-T cell for cancer therapy. Beni-Suef Univ J Basic Appl Sci 2022;11. [DOI: 10.1186/s43088-022-00238-8] [Reference Citation Analysis]
137 Mercier R, LaPointe P. The role of cellular proteostasis in anti-tumor immunity. J Biol Chem 2022;:101930. [PMID: 35421375 DOI: 10.1016/j.jbc.2022.101930] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
138 Raute K, Strietz J, Andrieux G, Thomas OS, Kistner KM, Zintchenko M, Aichele P, Zhou H, Weber W, Boerries M, Swamy M, Maurer J, Minguet S. Breast cancer stem cell-derived tumors escape from γδ T cell immunosurveillance in vivo by modulating γδ T cell ligands.. [DOI: 10.1101/2022.04.04.486931] [Reference Citation Analysis]
139 Emery A, Moore S, Turner JE, Campbell JP. Reframing How Physical Activity Reduces The Incidence of Clinically-Diagnosed Cancers: Appraising Exercise-Induced Immuno-Modulation As An Integral Mechanism. Front Oncol 2022;12:788113. [PMID: 35359426 DOI: 10.3389/fonc.2022.788113] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
140 Jasinski-Bergner S, Eckstein M, Taubert H, Wach S, Fiebig C, Strick R, Hartmann A, Seliger B. The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors. Front Immunol 2022;13:811200. [PMID: 35185904 DOI: 10.3389/fimmu.2022.811200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
141 Srour N, Villarreal OD, Hardikar S, Yu Z, Preston S, Miller WH Jr, Szewczyk MM, Barsyte-Lovejoy D, Xu H, Chen T, Del Rincón SV, Richard S. PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade. Cell Rep 2022;38:110582. [PMID: 35354055 DOI: 10.1016/j.celrep.2022.110582] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
142 Balasubramanian A, John T, Asselin-Labat ML. Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance. Biochem Soc Trans 2022:BST20210961. [PMID: 35343573 DOI: 10.1042/BST20210961] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
143 Zhang C, Li D, Xiao B, Zhou C, Jiang W, Tang J, Li Y, Zhang R, Han K, Hou Z, Zhang L, Sui Q, Liao L, Pan Z, Zhang X, Ding P. B2M and JAK1/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy. J Immunother 2022. [PMID: 35343934 DOI: 10.1097/CJI.0000000000000417] [Reference Citation Analysis]
144 Borden ES, Buetow KH, Wilson MA, Hastings KT. Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation. Front Oncol 2022;12:836821. [PMID: 35311072 DOI: 10.3389/fonc.2022.836821] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
145 Sangsuwannukul T, Supimon K, Chieochansin T, Choomee K, Sujjitjoon J, Junking M, Yenchitsomanus P. Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma. PLoS ONE 2022;17:e0265773. [DOI: 10.1371/journal.pone.0265773] [Reference Citation Analysis]
146 Molina ML, García-bernal D, Salinas MD, Rubio G, Aparicio P, Moraleda JM, Martínez S, Valdor R. Chaperone-Mediated Autophagy Ablation in Pericytes Reveals New Glioblastoma Prognostic Markers and Efficient Treatment Against Tumor Progression. Front Cell Dev Biol 2022;10:797945. [DOI: 10.3389/fcell.2022.797945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
147 Hesin A, Kumar S, Gahramanov V, Becker M, Vilenchik M, Alexandrov I, Yaglom J, Sherman MY. A Cell Double-Barcoding System for Quantitative Evaluation of Primary Tumors and Metastasis in Animals That Uncovers Clonal-Specific Anti-Cancer Drug Effects. Cancers (Basel) 2022;14:1381. [PMID: 35326533 DOI: 10.3390/cancers14061381] [Reference Citation Analysis]
148 Kalyanaraman B. Exploiting the tumor immune microenvironment and immunometabolism using mitochondria-targeted drugs: Challenges and opportunities in racial disparity and cancer outcome research. FASEB J 2022;36:e22226. [PMID: 35233843 DOI: 10.1096/fj.202101862R] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
149 Genova C, Dellepiane C, Carrega P, Sommariva S, Ferlazzo G, Pronzato P, Gangemi R, Filaci G, Coco S, Croce M. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. Front Immunol 2021;12:799455. [PMID: 35069581 DOI: 10.3389/fimmu.2021.799455] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
150 Martínez-jiménez F, Priestley P, Shale C, Baber J, Rozemuller E, Cuppen E. Genetic immune escape landscape in primary and metastatic cancer.. [DOI: 10.1101/2022.02.23.481444] [Reference Citation Analysis]
151 Garg S, Shekhawat U, Vohra R, Gupta R. Pretreatment Immune Status, Predicts Response to Definite Chemo Radiotherapy in Advanced Stages of Cervical Cancer Patients. J Obstet Gynecol India. [DOI: 10.1007/s13224-022-01624-z] [Reference Citation Analysis]
152 Dotse E, Lim KH, Wang M, Wijanarko KJ, Chow KT. An Immunological Perspective of Circulating Tumor Cells as Diagnostic Biomarkers and Therapeutic Targets. Life 2022;12:323. [DOI: 10.3390/life12020323] [Reference Citation Analysis]
153 Tarantino P, Corti C, Schmid P, Cortes J, Mittendorf EA, Rugo H, Tolaney SM, Bianchini G, Andrè F, Curigliano G. Immunotherapy for early triple negative breast cancer: research agenda for the next decade. NPJ Breast Cancer 2022;8:23. [PMID: 35181659 DOI: 10.1038/s41523-022-00386-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
154 Singh D, Afsar Khan M, Siddique HR. Specific Targeting of Cancer Stem Cells by Immunotherapy: A Possible Stratagem to Restrain Cancer Recurrence and Metastasis. Biochem Pharmacol 2022;:114955. [PMID: 35181312 DOI: 10.1016/j.bcp.2022.114955] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
155 He J, Xiong X, Yang H, Li D, Liu X, Li S, Liao S, Chen S, Wen X, Yu K, Fu L, Dong X, Zhu K, Xia X, Kang T, Bian C, Li X, Liu H, Ding P, Zhang X, Liu Z, Li W, Zuo Z, Zhou P. Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response. Cell Res 2022. [PMID: 35165422 DOI: 10.1038/s41422-022-00627-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
156 Sabbatino F, Liguori L, Pepe S, Ferrone S. Immune checkpoint inhibitors for the treatment of melanoma. Expert Opin Biol Ther 2022. [PMID: 35130816 DOI: 10.1080/14712598.2022.2038132] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Dastagir N, Beal Z, Godwin J. Tissue origin of cytotoxic natural killer cells dictates their differential roles in mouse digit tip regeneration and progenitor cell survival. Stem Cell Reports 2022;17:633-48. [PMID: 35120621 DOI: 10.1016/j.stemcr.2022.01.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
158 Liu R, Dollinger E, Nie Q. Machine Learning of Single Cell Transcriptomic Data From anti-PD-1 Responders and Non-responders Reveals Distinct Resistance Mechanisms in Skin Cancers and PDAC. Front Genet 2021;12:806457. [PMID: 35178072 DOI: 10.3389/fgene.2021.806457] [Reference Citation Analysis]
159 Elkoshi Z. Cancer and Autoimmune Diseases: A Tale of Two Immunological Opposites? Front Immunol 2022;13:821598. [DOI: 10.3389/fimmu.2022.821598] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
160 Njonkou R, Jackson CM, Woodworth GF, Hersh DS. Pediatric glioblastoma: mechanisms of immune evasion and potential therapeutic opportunities. Cancer Immunol Immunother 2022. [PMID: 35020009 DOI: 10.1007/s00262-021-03131-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Shevyrev D, Tereshchenko V, Kozlov V, Sennikov S. Phylogeny, Structure, Functions, and Role of AIRE in the Formation of T-Cell Subsets. Cells 2022;11:194. [PMID: 35053310 DOI: 10.3390/cells11020194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
162 Lee C, Seetharamu N. The Use of Immunotherapy in Cancer Patients with Autoimmune Diseases. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_63] [Reference Citation Analysis]
163 Cuyler J, Murthy P, Spada NG, McGuire TF, Lotze MT, Xie XQ. Sequestsome-1/p62-targeted small molecules for pancreatic cancer therapy. Drug Discov Today 2022;27:362-70. [PMID: 34592447 DOI: 10.1016/j.drudis.2021.09.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Hargadon KM, Wall JB. Combinatorial Strategies for T Lymphocyte-Based Cancer Immunotherapy. Handbook of Cancer and Immunology 2022. [DOI: 10.1007/978-3-030-80962-1_211-1] [Reference Citation Analysis]
165 Ye Z, Shi Y, Lees-Miller SP, Tainer JA. Function and Molecular Mechanism of the DNA Damage Response in Immunity and Cancer Immunotherapy. Front Immunol 2021;12:797880. [PMID: 34970273 DOI: 10.3389/fimmu.2021.797880] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
166 Demuynck R, Efimova I, Naessens F, Krysko DV. Immunogenic ferroptosis and where to find it? J Immunother Cancer 2021;9:e003430. [PMID: 34903554 DOI: 10.1136/jitc-2021-003430] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
167 Yang E, Chua W, Ng W, Roberts TL. Peripheral Cytokine Levels as a Prognostic Indicator in Gastric Cancer: A Review of Existing Literature. Biomedicines 2021;9:1916. [PMID: 34944729 DOI: 10.3390/biomedicines9121916] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
168 Pansy K, Uhl B, Krstic J, Szmyra M, Fechter K, Santiso A, Thüminger L, Greinix H, Kargl J, Prochazka K, Feichtinger J, Deutsch AJ. Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. Int J Mol Sci 2021;22:13311. [PMID: 34948104 DOI: 10.3390/ijms222413311] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
169 Retecki K, Seweryn M, Graczyk-Jarzynka A, Bajor M. The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance. Cancers (Basel) 2021;13:6012. [PMID: 34885122 DOI: 10.3390/cancers13236012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
170 Eptaminitaki GC, Wolff N, Stellas D, Sifakis K, Baritaki S. Long Non-Coding RNAs (lncRNAs) in Response and Resistance to Cancer Immunosurveillance and Immunotherapy. Cells 2021;10:3313. [PMID: 34943820 DOI: 10.3390/cells10123313] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
171 Huang YK, Busuttil RA, Boussioutas A. The Role of Innate Immune Cells in Tumor Invasion and Metastasis. Cancers (Basel) 2021;13:5885. [PMID: 34884995 DOI: 10.3390/cancers13235885] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
172 Habibzadeh P, Dastsooz H, Eshraghi M, Łos MJ, Klionsky DJ, Ghavami S. Autophagy: The Potential Link between SARS-CoV-2 and Cancer. Cancers (Basel) 2021;13:5721. [PMID: 34830876 DOI: 10.3390/cancers13225721] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
173 Cilibrasi C, Papanastasopoulos P, Samuels M, Giamas G. Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies. Int J Mol Sci 2021;22:12015. [PMID: 34769447 DOI: 10.3390/ijms222112015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
174 Zhou W, Xu S, Deng T, Zhou R, Wang C. LncRNA USP30-AS1 promotes the survival of acute myeloid leukemia cells by cis-regulating USP30 and ANKRD13A. Hum Cell 2021. [PMID: 34694569 DOI: 10.1007/s13577-021-00636-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
175 Noonepalle SKR, Karabon L, Chiappinelli KB, Villagra A. Editorial: Genetic and Epigenetic Control of Immune Responses. Front Immunol 2021;12:775101. [PMID: 34675944 DOI: 10.3389/fimmu.2021.775101] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
176 García-Sancha N, Corchado-Cobos R, Bellido-Hernández L, Román-Curto C, Cardeñoso-Álvarez E, Pérez-Losada J, Orfao A, Cañueto J. Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma. Cancers (Basel) 2021;13:5134. [PMID: 34680282 DOI: 10.3390/cancers13205134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
177 Ollivier L, Labbé M, Fradin D, Potiron V, Supiot S. Interaction Between Modern Radiotherapy and Immunotherapy for Metastatic Prostate Cancer. Front Oncol 2021;11:744679. [PMID: 34595122 DOI: 10.3389/fonc.2021.744679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
178 Batool S, Bin-T-Abid D, Batool H, Shahid S, Saleem M, Khan AU, Hamid A, Mahmood MS, Ashraf NM. Development of multi-epitope vaccine constructs for non-small cell lung cancer (NSCLC) against USA human leukocyte antigen background: an immunoinformatic approach toward future vaccine designing. Expert Opin Biol Ther 2021;21:1525-33. [PMID: 34547976 DOI: 10.1080/14712598.2021.1981285] [Reference Citation Analysis]
179 Kirkemo LL, Elledge SK, Yang J, Byrnes J, Glasgow J, Blelloch R, Wells JA. Cell-surface tethered promiscuous biotinylators enable small-scale surface proteomics of human exosomes.. [DOI: 10.1101/2021.09.22.461393] [Reference Citation Analysis]
180 Turchan WT, Pitroda SP, Weichselbaum RR. Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold. Int J Mol Sci 2021;22:9573. [PMID: 34502479 DOI: 10.3390/ijms22179573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
181 Sureshbabu SK, Godbole JH, Vaibhaw A, Chiplunkar SV. Immunosuppressive microenvironment in oral cancer: implications for cancer immunotherapy. Explor Immunol 2021. [DOI: 10.37349/ei.2021.00013] [Reference Citation Analysis]
182 Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med 2021;27:1345-56. [PMID: 34385702 DOI: 10.1038/s41591-021-01450-2] [Cited by in Crossref: 73] [Cited by in F6Publishing: 81] [Article Influence: 36.5] [Reference Citation Analysis]
183 Watanabe K, Nishikawa H. Engineering strategies for broad application of TCR-T and CAR-T cell therapies. Int Immunol 2021:dxab052. [PMID: 34374779 DOI: 10.1093/intimm/dxab052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
184 Srour N, Villarreal OD, Yu Z, Preston S, Miller WH, Szewczyk MM, Barsyte-lovejoy D, Xu H, del Rincón SV, Richard S. PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade.. [DOI: 10.1101/2021.07.28.454202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
185 Murtadha AH, Azahar IIM, Sharudin NA, Has ATC, Mokhtar NF. Influence of nNav1.5 on MHC class I expression in breast cancer. J Biosci 2021;46. [DOI: 10.1007/s12038-021-00196-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
186 Chen W, Shen L, Jiang J, Zhang L, Zhang Z, Pan J, Ni C, Chen Z. Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment. Biomark Res 2021;9:59. [PMID: 34294146 DOI: 10.1186/s40364-021-00312-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
187 Nguyen TB, Lane DP, Verma CS. Can Glycosylation Mask the Detection of MHC Expressing p53 Peptides by T Cell Receptors? Biomolecules 2021;11:1056. [PMID: 34356680 DOI: 10.3390/biom11071056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
188 Lv L, Wei Q, Wang Z, Zhao Y, Chen N, Yi Q. Clinical and Molecular Correlates of NLRC5 Expression in Patients With Melanoma. Front Bioeng Biotechnol 2021;9:690186. [PMID: 34307322 DOI: 10.3389/fbioe.2021.690186] [Reference Citation Analysis]
189 Shklovskaya E, Rizos H. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It. Int J Mol Sci 2021;22:6741. [PMID: 34201655 DOI: 10.3390/ijms22136741] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
190 Krenz B, Gebhardt-Wolf A, Ade CP, Gaballa A, Roehrig F, Vendelova E, Baluapuri A, Eilers U, Gallant P, D'Artista L, Wiegering A, Gasteiger G, Rosenfeldt MT, Bauer S, Zender L, Wolf E, Eilers M. MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma. Cancer Res 2021;81:4242-56. [PMID: 34145038 DOI: 10.1158/0008-5472.CAN-21-1677] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
191 Dymova MA, Kuligina EV, Richter VA. Molecular Mechanisms of Drug Resistance in Glioblastoma. Int J Mol Sci 2021;22:6385. [PMID: 34203727 DOI: 10.3390/ijms22126385] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]